Feng Jifeng

Feng Jifeng
1. Personal Information
Correspondence Address:
2. Education
(if applicable)
Xi'an Medical University, Xi’an, China
Clinical medicine
Southeast University, Nanjing, China
3. Research Interests
I have always engaged myself in tumor diagnosis and medical treatment, screening and cancer diagnosis, treatment and prognosis of the tumor marker, and to explore the molecular mechanism for cancer prevention and cancer treatment individualized to carry out a large number of basic and clinical applications. I not only found a number of tumor susceptibility genes and tumor incidence by molecular epidemiological studies, but also screened a number of treatment with tumor associated SNPs by molecular biology research. What's more, I carried out lung cancer recurrence, metastasis and prognosis tumor specific protein research. Through the cytological experiments and animal studies, by the application of gene knock in addition, transfection technology, I explored the mechanism of action of a number of genes in the development of lung cancer, I carried out the methods may as diagnosis, treatment and new drug development molecular targets. Apart from basic research at the same time, the applicant also chaired and participated in 67 new anticancer drug domestic and international, multi-center clinical trial research. In recent years, at Acta Biochimica et Biophysica Sinica, J Hum, Genet, Asian Pac J Cancer Prev Am J Clin Oncol, Cancer Chemother Pharmacol publications and many other research papers,he published more than 100 articles, edited or supervised 6 academic monographs.
4. Selected Publications
(1)Shen B, Shi MQ, Zheng MQ, Hu SN, Chen J, Feng JF.Correlation between polymorphisms of nicotine acetylcholine acceptor subunit CHRNA3 and lung cancer susceptibility.Mol Med Report. 2012 Dec;6(6):1389-92. doi: 10.3892/mmr.2012.1101. Epub 2012 Sep 26.
(2)Gong P, Huang XE, Chen CY, Liu JH, Meng AF, Feng JF.Comparison of Complications of Peripherally Inserted Central Catheters with Ultrasound Guidance or Conventional Methods in Cancer Patients.Asian Pac J Cancer Prev. 2012;13(5):1873-5.
(3)Wu Y, Sun WL, Feng JF.Antiangiogenic therapy in the management of breast cancer.Asia Pac J Clin Oncol. 2012 Jul 9. doi: 10.1111/j.1743-7563.2012.01569.x. [Epub ahead of print]

(4)Xu PP, Chen BA, Feng JF, Cheng L, Xia GH, Li YF, Qian J, Ding JH, Lu ZH, Wang XM, Xu K, Schultz M.Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia.Chin Med J (Engl). 2012 Jun;125(12):2137-43.
(5)Zhang XP, Bai ZB, Chen BA, Feng JF, Yan F, Jiang Z, Zhong YJ, Wu JZ, Chen L, Lu ZH, Tong N, Zhang ZD, Xu PP, Peng MX, Zhang WJ, Wang S.Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.Chin Med J (Engl). 2012 Mar;125(5):741-6.
(6)Yu S,Wu J,Xu S,Tan G,Liu B,Feng J.Modified PNA-PCR method:A convenient and accurate method to screen plasma KRAS mutations of cancer patients.Cancer Biol Ther.2012 Mar1;13(5).[Epub ahead of print]
(7)Zhong Y,Wu J,Chen B,Ma R,Cao H,Wang Z,Cheng L,Ding J,Feng J.Investigation and analysis of single nucleotide polymorphisms in Janus kinase/signal transducer and activator of transcription genes with leukemia.Leuk Lymphoma.2012 Jan 11.[Epub ahead of print]

(8)Shen B, Zheng MQ, Xu XY, Mo FG, Zhang T, Feng JF.[Expression of MT1-MMP and RECK protein in human gastric carcinoma].Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2011 Oct;25(5):364-7.

(9)Zhu XL, Sun XC, Chen BA, Sun N, Cheng HY, Li F, Zhang HM, Feng JF, Qin SK, Cheng L, Lu ZH.XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.Chin Med J (Engl). 2010 Dec;123(23):3427-32.
(10)F.Li,X.Sun,S.Qin,H.Cheng,J.Feng,B.Chen,L.Cheng,Z.Lu.Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.Am J Clin Oncol,2010,33:489-494.
(11)N.Sun,X.Sun,B.Chen,H.Cheng,J.Feng,L.Cheng,Z.Lu.MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.Cancer Chemother Pharmacol,2010,65:437-446.
(12)Zhong Y,Chen B,Feng J,Cheng L,Li Y,Qian J,Ding J,Gao F,Xia G,Chen N,Lu Z.The associations of Janus kinase-2(JAK2)A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia.Leuk Lymphoma.2010 Jun;51(6):1115-20.
(13)Yao CY, Huang XE, Li C, Shen HB, Shi MQ, Feng JF, Pan LX, Tang JH.Lack of Influence of XRCC1 and XPD Gene Polymorphisms on Outcome of Platinum-based Chemotherapy for Advanced Non Small Cell Lung Cancers.Asian Pac J Cancer Prev. 2009;10(5):859-64.
(14)Zhoang YJ, Chen BA, Cheng L, Feng JF, Li YF, Qian J, Ding JH, Cheng J, Gao F, Xia GH, Sun N, Zhang Y, Zhang XP, Xu PP, Lu ZH.[Detection of single nucleotide polymorphisms of Jak2 gene in multiple myeloma by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Oct;17(5):1234-7.
(15)Feng JF, Wu JZ, Hu SN, Gao CM, Shi MQ, Lu ZH, Sun XC, Zhou JR, Chen BA.Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer.Lung Cancer. 2009 Dec;66(3):344-9. Epub 2009 Mar 21
(16)J.F.Feng,X.Sun,N.Sun,S.Qin,F.Li,H.Cheng,B.Chen,Y.Cao,J.Ma,L.Cheng,Z.Lu,J.Ji,Y.Zhou.XPA A23G polymorphism is associated with the Elevated Response to Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer.Acta Biochimica et Biophysica Sinica,2009,41:429-435.
(17)X.Sun,F.Li,N.Sun,S.Qin,B.Chen,J.Feng,L.Cheng,Z.Lu,H.Cheng,Y.D.Cao,J.Ji,Y.Zhou.Polymorphisms in XRCC1 and XPG and respose to platinum-based chemotherapy in advanced non-small cell lung cancer patients.Lung Cancer,2009,65:230-236.
5. Scholarly and Professional Activities
Member,the Chinese Medical Association
Vice president,Chinese Medical Association oncologist branch of Clinical Oncology Chemotherapy Professional Committee
Vice chairman,the oncologist branch of Chinese Medical Doctor Association
Member,the Standing Committee of the Chinese Anti-Cancer Association tumor Professional Committee
Member,the Standing Committee of the Executive Committee of China Society of Clinical Oncology (CSCO)
Member,the lymphoma professional Committee of the China Anti-Cancer Association Member,the breast cancer professional Committee of the Chinese Anti-Cancer Association
Chairman,the oncology medicine and biological therapy branch of the Medical Association
Vice chairman,Cancer Hospital club of Jiangsu Provincial Hospital Association
Director,the Pharmaceutical Society of Jiangsu Province
Chairman,Jiangsu Province Anti-Cancer Association chemotherapy professional committee
Director,the Oncology medical quality control Center of Jiangsu Province
Director,Jiangsu Province Cancer Chemotherapy Center
Deputy editor,the"China surgical oncology magazine"
Editorial board,the" Practical Geriatrics "," Pharmaceutical and Clinical Research ",the "Journal of Clinical Oncology", "Chinese Journal of Cancer Prevention and Treatment" , "Journal of Nanjing Medical University" ,"cancer progression", "Journal of Clinical Oncology progress", "Oncology", "China practical Medicine", "pharmaceutical and clinical Research" magazine.